Zusammenfassung. Grundlagen: Retrospektive Analyse einer konsekutiven Serie von 30 Patienten, die aufgrund einer Femoralhernie operiert wurden.Methodik: Der Zeitpunkt der Diagnosestellung, der Zustand nach Operation einer Inguinalhernie und das Rezidiv nach Operation einer Femoralhernie wurden hinsichtlich des Einflusses auf die Notwendigkeit einer akuten Operation untersucht. Der postoperative chronische Schmerz wurde mittels VAS und MPQ-Score fü r akute und elektive Eingriffe verglichen. Nachbeobachtungszeitraum 50 Monate (Median).Ergebnisse: 11 Patienten (33,3%) wurden akut, 22 (67,7%) elektiv operiert. Der Zeitpunkt der Diagnosestellung unterschied sich je nachdem, ob die Operation akut oder elektiv durchgefü hrt wurde, signifikant in den beiden Gruppen (p ¼ 0,001). Ein Rezidiv ist nicht aufgetreten. Weder der Zustand nach Operation einer Inguinalhernie (p ¼ 0,212) noch das Rezidiv nach Operation einer Femoralhernie (p ¼ 0,143) sind signifikante Risikofaktoren fü r die Notwendigkeit einer akuten Operation. VAS und MPQ-Score zeigten keinen signifikanten Unterschied hinsichtlich akuter oder elektiver Operationen.Schlussfolgerungen: Weder der Zustand nach Operation einer Inguinalhernie noch ein Rezidiv nach Operation einer Femoralhernie sind signifikante Risikofaktoren für die Notwendigkeit einer akuten Operation. Die Inzidenz des postoperativen chronischen Schmerzes war bei akut und elektiv operierten Patienten vergleichbar.Schlüsselwörter: Femoralhernie, Rezidiv, chronischer Leistenschmerz.Summary. Background: Retrospective analysis of a consecutive series of 33 patients undergoing femoral hernia repair.Methods: Time from diagnosis to operation, previous inguinal hernia repair and recurrent femoral hernia were evaluated for their impact on the need to undergo emergency surgery. Postoperative chronic pain was measured by VAS and MPQ and compared for elective and emergency procedures.Results: Eleven patients (33.3%) had to undergo emergency surgery, while 22 (66.7%) were operated electively. Follow-up was 50 months in median (range 16-72). Overall, time periods between diagnosis and surgery differed significantly in acute and elective patients (p ¼ 0.001). Neither previous inguinal hernia repair (p ¼ 0.212) nor recurrent femoral hernia (p ¼ 0.143) increased the risk for acute operation. There was no recurrence. VAS and MPQ did not reveal a significant difference between emergency and elective patients.Conclusions: Previous inguinal hernia repair and recurrent femoral hernia do not increase the risk for emergency repair of femoral hernia. The incidence of postoperative chronic pain following acute and elective repairs was comparable.
Due to immunosuppressive therapy, transplant patients are more susceptible to viral and bacterial infections. A potentially deadly new virus haunted us in 2020: SARS-CoV-2, causing coronavirus disease 19 (COVID-19). We analyzed the consequences of this previously unknown risk for our living-donor transplant program in the first year of the pandemic. After the complete lockdown in spring 2020, our transplant center in Linz resumed the living-donor kidney transplantation program from June to September 2020, between the first and second waves of COVID-19 in Austria. We compared the outcomes of these living-donor kidney transplantations with the transplant outcomes of the corresponding periods of the three previous years. From June 4 to September 9, 2020, five living-donor kidney transplantations were performed. All donors and recipients were screened for COVID 19 infection by PCR testing the day before surgery. Kidney transplant recipients remained isolated in single rooms until discharge from hospital. All recipients and donors remained SARS-CoV-2 negative during the follow-up of 10 months and have been fully
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.